Receive our newsletter – data, insights and analysis delivered to you
  1. News
June 21, 2018

JenaValve Technology begins CE Mark study of Pericardial TAVR System

Transcatheter aortic valve replacement (TAVR) systems manufacturer JenaValve Technology has started patient enrolment and implantations for the CE Mark study of its new JenaValve Pericardial TAVR System.

Transcatheter aortic valve replacement (TAVR) systems manufacturer JenaValve Technology has started patient enrolment and implantations for the CE Mark study of its new JenaValve Pericardial TAVR System.

The implantations were carried out using the Coronatix Transfemoral Delivery Catheter for treating patients suffering from symptomatic, severe aortic regurgitation (AR).

The CE Mark study will involve a non-randomised single-arm trial of the JenaValve Pericardial TAVR System to assess its effectiveness in treating AR in patients showing an increased risk to undergo conventional surgical valve replacement.

“JenaValve Technology aims to complete patient enrolment by the end of this year at the clinical sites in Germany, the Netherlands, the US and New Zealand.”

Utilising the new 18-Fr equivalent Coronatix Transfemoral Delivery Catheter, the system enables more predictable implantation.

The national Principal Investigator, Dr Stephan Baldus said: “There is currently no TAVR treatment for severe aortic regurgitation cleared by regulators.

“These patients do not typically develop calcification at the implant site, so other TAVR valves that rely on this narrowing to anchor their devices are at risk of migration.

Content from our partners
The added value of Qarad’s multilingual freephone service to their eIFU solution
Small and simple: how medical device manufacturers select materials
Precision wire: The future of bespoke medical treatment

“The JenaValve transcatheter valve may address this issue by securing the device with three novel locators that grasp the native valve leaflets.”

JenaValve Technology aims to complete patient enrolment by the end of this year at the clinical sites in Germany, the Netherlands, the US and New Zealand.

It expects to secure CE Mark approval to treat patients with severe aortic regurgitation by the second half of next year.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU